| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$8 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jan 2026 8:30AM |
$0.096 |
$4.060 |
risen by
4,129.17%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive operating cash flow of $2,137,000 for the quarter.
- Receipts from customers totaled $4,579,000.
- Staff costs and administration expenses were significant.
- Investments of $2,007,000 in property, plant, and equipment.
- Net outflow of $517,000 from financing activities.
- Expansion by Tank Stream Labs and launch of The Founders Union.
- Successful revenue synergies from acquisitions.
- Cash balance of $867,000 at the end of the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Greatland Resources Limited (GGP) ORDINARY FULLY PAID |
Materials |
$7,394 |
December 2025 Quarterly Activities Report
|
28 Jan 2026 8:28AM |
$13.980 |
$10.960 |
fallen by
21.60%
|
|
GGP - Price-sensitive ASX Announcement
Full Release
Key Points
- Greatland produced 86,273 ounces of gold and 3,528 tonnes of copper in the December 2025 quarter.
- The all-in sustaining cost (AISC) was $2,196 per ounce of gold.
- Cash flow from operations was $406 million, with a closing cash balance of $948 million.
- Havieron Feasibility Study confirmed it as a world-class, low-cost gold-copper mine.
- Quarterly growth capital expenditure was $90.3 million, focusing on Telfer and Havieron.
- Entered into a $500 million corporate debt commitment with major banks.
- Paid a one-off $46 million stamp duty for the Telfer-Havieron acquisition.
- The company remained debt-free with significant liquidity.
- Safety improvements were made, reducing the TRIFR.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ragusa Minerals Ltd (RAS) ORDINARY FULLY PAID |
Materials |
$4 |
Private Placement to Raise $600,000
|
28 Jan 2026 8:28AM |
$0.035 |
$0.018 |
fallen by
48.57%
|
|
RAS - Price-sensitive ASX Announcement
Full Release
Key Points
- Private Placement to raise $600,000 at $0.03 per share
- Placement supported by existing key shareholders
- Funds to support exploration at Purple Pansy Manganese-Gold Project
- Settlement expected on 28 January 2026, shares issued on 29 January 2026
- Placement available to sophisticated and professional investors
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Develop Global Limited (DVP) ORDINARY FULLY PAID |
Materials |
$1,723 |
Quarterly Activities Report - December 2025
|
28 Jan 2026 8:28AM |
$5.510 |
$5.220 |
fallen by
5.26%
|
|
DVP - Price-sensitive ASX Announcement
Full Release
Key Points
- Steady-state production at Woodlawn expected by March quarter 2026.
- Final investment decision for Sulphur Springs anticipated for June 2026.
- Two years into a five-year plan aiming for 50ktpa copper-equivalent metal.
- Woodlawn achieved record processing of 59,000t in December.
- Sulphur Springs projected pre-tax NPV of A$1.15B at spot prices.
- Develop Mining Services secured A$200m contract with OceanaGold.
- Group external revenue reached A$94.6m.
- Cash position at A$179.9m as of December 31, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$87 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jan 2026 8:27AM |
$0.585 |
$0.475 |
fallen by
18.80%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma reached over 1,000 SPONTAN prescriptions under the TGA Special Access Scheme.
- Ethics approval and TGA regulatory clearance were received for the SPONTAN Phase II study.
- First patients were dosed in the Phase II study with initial data expected in Q2 CY2026.
- ROXUS development is on track for a planned US market launch in H1 CY2026.
- Strong cash balance of A$25.9 million as of 31 December 2025.
- Strategic investment was made in LevOmega Pty Ltd to increase ownership from 33% to 43%.
- Net cash used in operating activities was A$2,756,523 for the quarter.
- Total cash and cash equivalents at the end of the quarter were A$25,937,281.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$10,380 |
4Q 2025 Trading Update
|
28 Jan 2026 8:27AM |
$30.330 |
$43.560 |
risen by
43.62%
|
|
ALD - Price-sensitive ASX Announcement
Full Release
Key Points
- 4Q 2025 Lytton Refiner Margin of US$15.14 per barrel.
- Group RCOP EBIT for FY 2025 of approximately $945 million.
- Group RCOP EBITDA for FY 2025 of approximately $1,435 million.
- Consistent performance from Australian Convenience Retail business.
- Stable EBIT in New Zealand despite economic challenges.
- Modest profit from F&I International focusing on Ampol system.
- Full-year audited results to be released on 23 February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Control Bionics Limited (CBL) ORDINARY FULLY PAID |
Health Care |
$34 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jan 2026 8:27AM |
$0.067 |
$0.062 |
fallen by
7.46%
|
|
CBL - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant capital raise of over $3.8 million.
- Partnership with Tobii for NeuroNode® distribution.
- Integration with Apple’s BCI protocol.
- Acquisition of Neuro Elite Athletics for US Sports Performance program.
- NeuroStrip® expansion with scaled manufacturing.
- Cash receipts of $1.4 million affected by NDIS delays.
- Closing cash balance of $3.1 million.
- Strategic focus on profitability and growth in core markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Develop Global Limited (DVP) ORDINARY FULLY PAID |
Materials |
$1,723 |
Quarterly Appendix 5B Cash Flow Report - December 2025
|
28 Jan 2026 8:26AM |
$5.510 |
$5.220 |
fallen by
5.26%
|
|
DVP - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash inflow from operating activities of $18.755 million for the quarter.
- Net cash outflow from investing activities of $29.514 million for the quarter.
- Net cash outflow from financing activities of $13.152 million for the quarter.
- Cash balance at the end of the quarter was $179.878 million.
- Loan facility with Trafigura Pte Ltd fully drawn at $108.5 million.
- Equipment financing with Sandvik, CBA, Eprioc, Cat Finance and NAB.
- Total available funding at quarter end was $240.274 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rapid Critical Metals Limited (RCM) ORDINARY FULLY PAID |
Materials |
$36 |
Commencement of Scoping Study for NSW Silver Projects
|
28 Jan 2026 8:26AM |
$0.085 |
$0.030 |
fallen by
64.71%
|
|
RCM - Price-sensitive ASX Announcement
Full Release
Key Points
- Commencement of Scoping Study for NSW silver projects.
- Appointment of METS Engineering Group for study management.
- Focus on process design and cost estimates.
- Encouraging preliminary ore-sorting results.
- Pending assay results from recent drilling.
- Applications for additional drilling submitted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$310 |
St George Appoints US Government Adviser
|
28 Jan 2026 8:23AM |
$0.110 |
$0.066 |
fallen by
40%
|
|
SGQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Appointment of Ervin Graves Strategy Group for US engagement.
- Araxá Project located in Minas Gerais, Brazil.
- Largest and highest-grade carbonatite-hosted rare earth deposit in South America.
- Strategic alignment with US policy on critical minerals.
- Potential for government funding and industry partnerships in the US.
- St George Mining aims to contribute to US critical mineral supply chains.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hazer Group Limited (HZR) ORDINARY FULLY PAID |
Materials |
$83 |
Investor Webinar Presentation
|
28 Jan 2026 8:23AM |
$0.480 |
$0.310 |
fallen by
35.42%
|
|
| 360 Capital Group (TGP) ORDINARY FULLY PAID |
Financials |
- |
Notice of Compulsory Acquisition
|
28 Jan 2026 8:22AM |
$0.310 |
$0.300 |
fallen by
3.23%
|
|
| 29Metals Limited (29M) ORDINARY FULLY PAID |
Materials |
$665 |
Retail Entitlement Offer Opens
|
28 Jan 2026 8:22AM |
$0.480 |
$0.380 |
fallen by
20.83%
|
|
29M - Price-sensitive ASX Announcement
Full Release
Key Points
- Retail Entitlement Offer opens on 28 January 2026.
- Offer price is $0.40 per new share.
- Approximately $31 million expected to be raised from retail offer.
- The offer is part of a larger $150 million equity raising effort.
- Eligible shareholders are in Australia and New Zealand.
- Non-participating shareholders will experience equity dilution.
- Funds to support strategic growth and ongoing projects.
- Offer closes on 11 February 2026.
- Proceeds to aid in feasibility studies and investment in key projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Advance Metals Limited (AVM) ORDINARY FULLY PAID |
Materials |
$28 |
Quarterly Activity and Cashflow Report
|
28 Jan 2026 8:21AM |
$0.185 |
$0.057 |
fallen by
69.19%
|
|
AVM - Price-sensitive ASX Announcement
Full Release
Key Points
- Fully funded drilling program at Yoquivo Silver-Gold Project.
- Historic core resampling confirms high-grade silver-gold mineralization.
- Appointment of a Mexico-focused Advisory Board and a Non-Executive Chairman.
- Completion of a $13 million institutional placement.
- Ongoing exploration at Myrtleford Gold Project with significant gold findings.
- Net cash inflow primarily from financing activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Teaminvest Private Group Limited (TIP) ORDINARY FULLY PAID |
Financials |
$37 |
Update - Notification of buy-back - TIP
|
28 Jan 2026 8:21AM |
$1.585 |
$1.370 |
fallen by
13.56%
|
|
| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$214 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jan 2026 8:21AM |
$0.042 |
$0.930 |
risen by
2,114.29%
|
|
BXN - Price-sensitive ASX Announcement
Full Release
Key Points
- Record $17.2 million quarterly revenue, 112% increase on Q2 FY25.
- Positive $2.5 million cash flow from operating activities in Q2 FY26.
- Completed dual listing on Frankfurt Stock Exchange (ticker: PR8.F).
- Executed exclusive agreement with Curaleaf International for Que Medical Inhalation Device.
- Fulfilling orders for Australian-manufactured MDMA capsules for clinical trials.
- Secured £848,250 funding for UK GMP manufacturing facility.
- Ending cash balance of $7.6 million as of 31 December 2025.
- Focused on international expansion and operational efficiencies.
- On track to achieve FY26 guidance of $65–$75 million in revenue and $11.5–$13.5 million EBITDA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tetratherix Limited (TTX) ORDINARY FULLY PAID |
Health Care |
$183 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jan 2026 8:21AM |
$3.830 |
$6.200 |
risen by
61.88%
|
|
TTX - Price-sensitive ASX Announcement
Full Release
Key Points
- BioOptix partnership with Alcon involves milestone-based development funding.
- Tutelix cohort 2 patient recruitment is progressing.
- Strong cash position of $21.6 million with zero debt as of 31 December 2025.
- Significant R&D investment in bone regeneration products Tegenix and TegenEOS.
- Construction of a new manufacturing facility in Alexandria.
- Distribution agreement with Henry Schein for Tegenix's commercialization.
- Eligibility for R&D tax incentive confirmed for FY25-FY27.
- TetraDerm clinical trial moving to third cohort with positive safety profile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coronado Global Resources Inc (CRN) CHESS DEPOSITARY INTERESTS 10:1 |
Materials |
$348 |
Quarterly Activities Report Q4 2025
|
28 Jan 2026 8:21AM |
$0.455 |
$0.208 |
fallen by
54.40%
|
|
CRN - Price-sensitive ASX Announcement
Full Release
Key Points
- Coronado achieved highest quarterly and half-year sales volumes since FY21.
- Total revenues for Q4 2025 were $550.5 million.
- Met Coal sales were the primary revenue driver.
- 15% reduction in mining costs since FY21.
- Strategic focus on asset management, product mix optimization, and debt reduction.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cleanaway Waste Management Limited (CWY) ORDINARY FULLY PAID |
Industrials |
$5,986 |
Cleanaway appoints Dr Vanessa Guthrie AO to the Board
|
28 Jan 2026 8:21AM |
$2.510 |
$2.670 |
risen by
6.37%
|
|
| Ore Resources Limited (OR3) ORDINARY FULLY PAID |
Materials |
$59 |
Quarterly Activities / Appendix 5B Cash Flow Report
|
28 Jan 2026 8:21AM |
$0.079 |
$0.071 |
fallen by
10.13%
|
|
OR3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Completed Phase 3 drilling at Forrest with significant gold assays.
- Randalls project identified multiple high-priority gold targets.
- Successful A$7.5M placement to fund exploration.
- Net cash from operating activities was negative A$440,000 for the quarter.
- Cash and cash equivalents at the end of the quarter were A$10,690,000.
- Planned over 30,000 meters of drilling for 2026 across projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Benz Mining Corp (BNZ) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$1,855 |
Becoming a substantial holder
|
28 Jan 2026 8:21AM |
$2.250 |
$4.890 |
risen by
117.33%
|
|
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$351 |
Update - Notification of buy-back - RG8
|
28 Jan 2026 8:21AM |
$2.980 |
$2.500 |
fallen by
16.11%
|
|
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$591 |
Update - Notification of buy-back - RG1
|
28 Jan 2026 8:20AM |
$2.520 |
$2.550 |
risen by
1.19%
|
|
| Saluda Medical, Inc. (SLD) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$103 |
Quarterly Investor Presentation
|
28 Jan 2026 8:20AM |
$1.190 |
$0.408 |
fallen by
65.76%
|
|
| Saluda Medical, Inc. (SLD) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$103 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jan 2026 8:20AM |
$1.190 |
$0.408 |
fallen by
65.76%
|
|
SLD - Price-sensitive ASX Announcement
Full Release
Key Points
- Saluda listed on the ASX on 5 December 2025, raising A$230.8 million.
- Achieved global revenue of US$21.0 million in Q2 FY26, a 19.9% increase.
- US implanted patient growth was 21.2% in Q2 FY26.
- Increased FY26 revenue guidance to US$85 million, a 21% year-over-year growth.
- Regulatory approval for EVA™ Sensing Technology in Europe and Australia.
- Executed a phased reduction in workforce to manage operating expenses.
- Expanded US sales force to 89 trained reps, with plans for further expansion.
- Hosted an investor webinar to discuss Q2 FY26 results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
